Author Archive for Insider Scoop

Bristol-Myers Oncology Growth Potential Remains High

Courtesy of Benzinga.

Bristol-Myers Oncology Growth Potential Remains High

Bristol-Myers Squibb Co (NYSE: BMY) “has named three independent directors to its board amid reports that JANA Partners and Carl Icahn have taken stakes in BMY,” said Argus’ David Toung in a note, while reiterating a Buy rating on the company, with a price target of $75.

Board Changes

The analyst mentioned that Bristol Myers Squibb has also raised speculation that the company would be more open to increasing shareholder value with the addition of three independent board members, following discussions with activist investor, JANA Partners.

JANA Partners had disclosed in a filing in mid-February that it owned Bristol-Myers Squibb stock worth $226 million, representing 0.2 percent interest.

“Bristol-Myers has also attracted interest from Carl Icahn, according to reports in Bloomberg and other news outlets, who took a stake in BMY after the announcement of the new board appointments and a $2 billion accelerated stock repurchase program,” Toung stated.

The size of Icahn’s stake in the company is as yet undisclosed.

Related Link: Wall Street’s M&A Chatter From February 21

Oncology Drug

The analyst expects the company’s oncology drug, Opdivo, to face heightened competition in 2017, although the drug is also expected to gain additional approvals over the next 22 months, adding to its 10 indications at present.

“BMY also expects data readouts from Phase 2 and 3 clinical trials that could lead to FDA filings for expanded indications, including first-line positioning in non-small-cell lung cancer, melanoma, renal cell carcinoma, and hepatocellular carcinoma,” Toung explained.

“We continue to like the company’s long-term prospects and the growth potential of its oncology portfolio,” the analyst added.

Image Credit: By Avarrial (Own work) [CC BY-SA 4.0], via Wikimedia Commons

Latest Ratings for BMY

Date Firm Action From To
Dec 2016 Jefferies Upgrades Hold Buy
Oct 2016 Hilliard Lyons Upgrades Neutral Long-Term Buy
Oct 2016 Credit Suisse Maintains Neutral

View More Analyst Ratings for BMY

View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Reiteration Analyst Ratings Movers Best of Benzinga

Argus Raises Home Depot’s Target To $160 Following Big Q4 Beat

Courtesy of Benzinga.

Argus Raises Home Depot's Target To $160 Following Big Q4 Beat

Argus reiterated its Buy rating and raised its price target on Home Depot Inc (NYSE: HD) by $6 to $160, which implies total return potential of about 13.5 percent including the dividend yield of about 2.5 percent.

The price target change comes after better-than-expected quarterly results from the home improvement retailer. Home Depot reported fourth quarter EPS of $1.44, above the average analyst estimate of $1.33. Comp sales at U.S. stores were up an impressive rate of 6.3 percent, handily topping consensus of 3.5 percent.

Analyst Commentary

Analyst Chris Graja sees continued upside for the shares, despite providing more than double the returns of the S&P 500 over the last two years.

“Increasing returns on capital, signs of improving customer service during recent store visits, rising home prices, and impressive execution of the business plan support our conviction that even after raising the operating margin by more than 450 basis points over the last five years, Home Depot still has room to increase earnings and profitability,” Graja wrote in a note.

Related Link: Large Supplier Checks Have Favorable Read Through For Home Depot, Lowe’s

On the sector front, home prices are only now reaching 2006 peak levels and affordability is still positive. In addition, about two-thirds of U.S. homes are more than 25 years old and likely in need of upgrades and repairs.

Notably, Home Depot has surpassed its financial targets ahead of schedule. It beat its goal of a 13 percent operating margin and a 27 percent ROIC by the end of FY 2016, and set a new goal to raise the operating margin to 14.5 percent and ROIC to 35 percent over the following three years.

“We believe that HD will reach its target for operating margin in the current FY18, which is a year ahead of schedule,” the analyst added.

Shares of Home Depot closed Tuesday’s trading at $145.02.

image Credit: By Tomwsulcer – Own work, CC0,
continue reading

Resunab Can Change The Game In Cystic Fibrosis

Courtesy of Benzinga.

Resunab Can Change The Game In Cystic Fibrosis

A conference call with cystic fibrosis specialists indicated that the disease continued to be characterized by “a vicious cycle of mucus secretion, infection and inflammation,” Cantor Fitzgerald’s Elemer Piros said in a report. He added that the call reinforced “our view that Resunab has potential to meaningfully alter this vicious cycle through resolution of CF’s inflammation component.”

Piros reiterated an Overweight rating on Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP), with a price target of $17.

Resunab’s Effect On Inflammation

There have been several failed attempts at addressing inflammation. nonsteroidal anti-inflammatory drugs, corticosteroids and azithromycin all have limitations in terms of their efficacy or usage. The development of a Leukotriene B4 antagonist had been discontinued because of its effect of increased pulmonary exacerbations versus placebo, Piros mentioned.

Related Link: Corbus Soars 65% On Top Line Phase 2 Results/>

“We left the call with a greater appreciation for the focus of safety in Corbus’ Phase 2 study, which underscores CF patients’ potential for altered pharmacokinetics and vigilance of immunosuppression. Resunab potentially avoids these negative liabilities by promoting resolution of inflammation, instead of inhibiting the inflammatory cascade,” the analyst wrote.

The readout of Corbus Pharma’s Phase 2 study is expected this quarter, which should provide more insight into Resunab’s effect on inflammation. Piros assigned a 30 percent probability of success for Resunab for the three indication — cystic fibrosis, diffuse cutaneous systemic sclerosis and dermatomyositis programs — all of which are currently in Phase 2 development.

Latest Ratings for CRBP

Date Firm Action From To
Oct 2016 Cantor Fitzgerald Initiates Coverage on Buy
Oct 2016 Cantor Fitzgerald Initiates Coverage on Buy
Mar 2016 Aegis Capital Initiates Coverage on Buy

View More Analyst Ratings for CRBP

View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Reiteration Analyst Ratings Movers Best of Benzinga

Q4 Casual Dining Cage Match: Texas Roadhouse Vs. Red Robin

Courtesy of Benzinga.

Q4 Casual Dining Cage Match: Texas Roadhouse Vs. Red Robin

Against a challenging restaurant environment, Texas Roadhouse Inc (NASDAQ: TXRH) and Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) announced weak Q4 same-store sales. Both companies should generate better results in fiscal year 2017, Stephens’ Will Slabaugh said in a report.

Slabaugh has the price target for Texas Roadhouse at $48 and that for Red Robin at $75, with Overweight ratings on both companies.

Texas Roadhouse

The company reported company-owned SSS at +1.2 percent, versus the consensus expectation of 3.2 percent. Adjusted EPS for the quarter came in at $0.29, missing the consensus estimate of $0.38.

“On the bottom line, wage rate inflation and higher costs associated with payroll taxes and insurance adjustments more than offset continued beef favorability,” Slabaugh noted.

Texas Roadhouse indicated that its quarter-to-date SSS had tracked up 1.5 percent, versus the consensus projection of 3.1 percent for the first quarter. The company guided to positive SSS for FY 2017, with mid-single-digit labor inflation, food cost deflation of 1–2 percent and the opening of 30 company restaurants, including six Bubba’s.

Related Link: Highlights From 3 Restaurant CEO Chats With CNBC

Red Robin

The company reported its SSS down 4.3 percent, with a 2.9 percent decline in traffic. This came in marginally better than its preannouncement. EPS was recorded at $0.35, ahead of consensus expectations of $0.29.

For FY 2017, Red Robin guided to EPS of $2.70–$3.00 and adjusted EBITDA of $145–$150 million, versus the consensus expectations of $2.88 and $146 million, respectively. The comp guidance for the year also came ahead of expectations, at 0.5–1.5 percent. The analyst expects the company’s comps growth to be “somewhat back-half loaded.”

“The soft quarter was widely expected after its presentation at…
continue reading

A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Fed Minutes

Courtesy of Benzinga.

A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Fed Minutes

Pre-open movers

U.S. stock futures traded slightly lower in early pre-market trade. Data on existing home sales for January will be released at 10:00 a.m. ET. Federal Reserve Gov. Jerome Powell is set to speak at the Forecaster’s Club of New York at 1:00 p.m. ET, while the Federal Open Market Committee will issue minutes of its latest meeting at 2:00 p.m. ET.

Futures for the Dow Jones Industrial Average dropped 12 points to 20,676.00, while the Standard & Poor’s 500 index futures fell 3.75 points to 2,356.25. Futures for the Nasdaq 100 index slipped 4.25 points to 5,339.50.

Oil prices traded lower as Brent crude futures declined 0.46 percent to trade at $56.40 per barrel, while US WTI crude futures fell 0.52 percent to trade at $54.05 a barrel.

A Peek Into Global Markets

European markets were mostly lower today, with the Spanish Ibex Index falling 0.62 percent, STOXX Europe 600 Index declining 0.10 percent and German DAX 30 index gaining 0.07 percent. The UK’s FTSE index was trading higher by 0.06 percent, while French CAC 40 Index fell 0.07 percent.

In Asian markets, Japan’s Nikkei Stock Average fell 0.01 percent, Hong Kong’s Hang Seng Index climbed 0.99 percent, China’s Shanghai Composite Index climbed 0.24 percent and India’s BSE Sensex rose 0.36 percent.

Broker Recommendation

Analysts at Bank of America downgraded United Parcel Service, Inc. (NYSE: UPS) from Buy to Neutral.

UPS shares fell 1.60 percent to $106.00 in pre-market trading.

Breaking news

  • DISH Network Corp (NASDAQ: DISH) reported better-than-expected earnings for its fourth quarter.
  • Garmin Ltd. (NASDAQ: GRMN) reported upbeat results for its fourth quarter on Wednesday.
  • Toll Brothers Inc (NYSE: TOL) posted stronger-than-expected results for its first quarter on Wednesday.
  • First Solar, Inc. (NASDAQ: FSLR) reported better-than-expected results for its fourth quarter and raised its FY17 revenue forecast.

Posted-In: A Peek Into The MarketsEarnings News Eurozone Futures Global Pre-Market Outlook Markets

Discovery Communications Shares Finally Trading In Line With Growth; Loop Drops From Buy To Hold

Courtesy of Benzinga.

Discovery Communications Shares Finally Trading In Line With Growth; Loop Drops From Buy To Hold

Loop Capital has downgraded Discovery Communications Inc. (NASDAQ: DISCA) to Hold from Buy, saying the stock now prices in the growth prospects and potential dividend effects. The stock is trading a mere 4.7 percent shy of its target of $31.00.

“While it has not happened yet, we also believe the stock price today reflects the creation of a modest $0.30/sh dividend,” analyst David Miller wrote in a note.

Miller also noted that investors are undervaluing Discovery’s scale and scope within the international business as it reaches over 883 million households in 178 countries.

As of fourth quarter, Discovery’s International Networks accounts for 46.8 percent of revenues and 35 percent of adjusted EBITDA, making it the most “international” media company amongst all large-cap peers.

Related Link: What is a Best of Breed Stock?

Miller also expects Discovery to initiate a dividend of $0.30 a share, given the slowing growth rate, an improvement in 2016 free cash flow (FCF) of 9.5 percent and $1.36 billion plus in FCF expected in 2017.

At last check, shares of Discovery fell 1.01 percent to $29.32.

Image Credit: By John from Live in DC, Work in Baltimore – discovery, CC BY 2.0, via Wikimedia Commons

Latest Ratings for DISCA

Date Firm Action From To
Feb 2017 Loop Capital Downgrades Buy Hold
Feb 2017 Deutsche Bank Initiates Coverage On Neutral Hold
Jan 2017 Pivotal Research Downgrades Buy Hold

View More Analyst Ratings for DISCA

View the Latest Analyst Ratings

Posted-In: Analyst Color News Downgrades Price Target Analyst Ratings Movers Tech Media Best of Benzinga

Mid-Morning Market Update: Markets Open Higher; Wal-Mart Earnings Beat Views

Courtesy of Benzinga.

Following the market opening Tuesday, the Dow traded up 0.38 percent to 20,702.96 while the NASDAQ gained 0.36 percent to 5,859.49. The S&P also rose, gaining 0.36 percent to 2,359.65.

Leading and Lagging Sectors

Energy shares climbed by 0.91 percent in trading on Tuesday. Meanwhile, top gainers in the sector included Helix Energy Solutions Group Inc (NYSE: HLX), and Seadrill Ltd (NYSE: SDRL).

In trading on Tuesday, industrial shares fell by 0.16 percent. Meanwhile, top losers in the sector included Unilever N.V. (ADR) (NYSE: UN), down 8 percent, and Westinghouse Air Brake Technologies Corp (NYSE: WAB), down 6 percent.

Top Headline

Wal-Mart Stores Inc (NYSE: WMT) reported better-than-expected earnings for its fourth quarter on Tuesday.

Wal-Mart posted Q4 earnings of $1.30 per share on revenue of $130.94 billion. However, analysts were expecting earnings of $1.29 per share on revenue of $131.22 billion.

Equities Trading UP

Delta Natural Gas Company, Inc. (NASDAQ: DGAS) shares shot up 15 percent to $30.10 after the company agreed to be acquired by Peoples Gas for $30.50 per share in cash.

Shares of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) got a boost, shooting up 35 percent to $2.22 as the company reported a licensing agreement with Valeant Pharmaceuticals Intl Inc (NYSE: VRX).

Community Health Systems (NYSE: CYH) shares were also up, gaining 31 percent to $9.06 after reporting upbeat Q4 results.

Equities Trading DOWN

Trevena Inc (NASDAQ: TRVN) shares dropped 34 percent to $4.68 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called “APOLLO-1″ and “APOLLO-2.” The studies evaluated the safety of Trevena’s…
continue reading

Why miRagen Therapeutics Shares Could See 60% Upside By 2018

Courtesy of Benzinga.

Why miRagen Therapeutics Shares Could See 60% Upside By 2018

Miragen Therapeutics, Inc. (NASDAQ: MGEN) appears to be an “attractive investment opportunity,” with its microRNA pipeline demonstrating early clinical efficacy, the presence of near-term catalysts and the potential for “multi-billion dollars in product sales,” Wedbush’s Liana Moussatos said in a report.

Moussatos initiated coverage of miRagen Therapeutics with an Outperform rating and a price target of $19.

Promising Lead Candidates

“Using established microRNA disease targets and pathways, each program is progressively de-risked early in development,” Moussatos wrote. miRagen Therapeutics currently has two lead programs, namely MRG- 106, a miR-155 inhibitor for hematologic malignancies, and MRG-201, a miR-29 mimetic for fibrotic diseases.

“Both programs have established clinical proof of mechanism, demonstrated single dose target engagement, initial efficacy and an acceptable safety and tolerability profile in our view,” the analyst commented.

Related Link: miRagen Therapeutics and Signal Genetics Sign Merger Agreement

Market Potential

The gross peak annual sales of MRG-106 is estimated to reach ~$1 billion in 2030 for cutaneous T-cell lymphomas–mycosis fungoides, while a potential expansion into diffuse large B-cell lymphoma, chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma could contribute an additional $1 billion in 2027, Moussatos said.

“We project MRG-201 can achieve about $90 million for peak sales in 2028 for skin fibrosis indications (keloids). However, we see more commercial potential to treat other fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) which we project gross peak annual sales could reach over $1 billion in 2028,” the analyst wrote.

MiRagen Therapeutics announced it has ~$60 million in cash. This would likely last through 2018, the Wedbush report added.

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Analyst Ratings Trading Ideas General Best of Benzinga

Verizon Will Pay $350 Million Less For Yahoo’s Operating Business

Courtesy of Benzinga.

Verizon Will Pay $350 Million Less For Yahoo's Operating Business

Verizon Communications Inc. (NYSE: VZ)’s proposed acquisition of Yahoo! Inc. (NASDAQ: YAHOO)’s operating business was finalized Tuesday.

Deal Details

The deal was put on hold earlier this year after the internet giant disclosed new revelations about various security breaches.

Reports surfaced last week that the acquisition was still on track to close but at a slightly lower price tag. A Bloomberg report on February 15 suggested that Yahoo will shave $250 million off the acquisition price, but a joint press release from the two companies confirmed Verizon will pay $350 million less for the operating business.

The new price tag on the deal stands at $4.48 billion in cash and is subject to closing adjustments and expected to close in the second quarter of 2017.

Related Link: Verizon’s Network Has A New Top Competitor, And It’s Not AT&T

The press release also noted that Verizon and Yahoo will share some of the legal and regulatory liabilities from the data breaches. Specifically, Yahoo will be responsible for 50 percent of any cash liabilities and liabilities arising from shareholder lawsuits and Securities and Exchange Commission investigations will be the responsibility of Yahoo.

Leadership Commentary

Marni Walden, Verizon executive vice president and president of Product Innovation and New Businesses, said: “We have always believed this acquisition makes strategic sense. We look forward to moving ahead expeditiously so that we can quickly welcome Yahoo’s tremendous talent and assets into our expanding portfolio in the digital advertising space.”

Walden added, “The amended terms of the agreement provide a fair and favorable outcome for shareholders. It…
continue reading

Dick’s Sporting Goods Downgraded On Wave Of Negative Industry Data

Courtesy of Benzinga.

Dick's Sporting Goods Downgraded On Wave Of Negative Industry Data

Oppenheimer downgraded Dicks Sporting Goods Inc (NYSE: DKS) to Perform from Outperform on wave of negative data points.

The downgrade comes ahead of the company’s fourth-quarter results in mid-March. Recently, a large number of leading sporting goods manufacturers and retailers reported results lower than expectations.

Holiday 2016 sales were dampened due to unfavorable weather, disruptions in replenishment and generally weak demand.

Against this backdrop, the brokerage noted that even the well-positioned Dick’s Sporting Goods is unlikely to emerge from this sector headwind unscathed.

Deflating Dick’s

“The market continues to wager on the potential for improved sales and EPS growth at DKS in coming quarters. Hints of a setback in Q4 (Jan. 2017) or into FY17 (Jan. 2018) are likely to undermine near-term investor confidence in the DKS story,” analyst Brian Nagel wrote in a note.

Related Link: Apple’s iPhone 8 Launch Likely To Hurt…Shoe Retailers?

As such, Nagel cut his fourth quarter EPS forecast to $1.27 from $1.30 versus a current Street figure of $1.30 and management earnings guidance of $1.19–$1.31. The analyst also slashed his fiscal 2017 (Jan. 2018) EPS view to $3.62 from $3.75 versus current consensus estimate of $3.78.

Nagel also warned that more challenging comparisons loom for the company post fourth quarter. Comp sales comparisons step up to +2.8 percent in the second quarter (July) and +5.2 percent in the third quarter (October) as the company begins to lap the benefits of market share shifts that occurred in mid-2016.

Consequently, the analyst adopted a cautious stance despite acknowledging the fact that the company remains the preeminent market share taker in the sector following recent significant competitive fallout.

At last check, shares of Dick’s Sporting Goods were up 0.64 percent at $50.07.

Latest Ratings for DKS

Date Firm Action From To
Jan 2017 Goldman Sachs Upgrades Neutral Buy
Nov 2016 Wedbush Initiates Coverage On Outperform
Oct 2016 Cowen & Co. Upgrades Market Perform Outperform

View More Analyst Ratings for DKS

View the Latest Analyst Ratings

Posted-In: Analyst Color Earnings News Downgrades Price Target Previews Sports Analyst Ratings Best of Benzinga


Zero Hedge

Recession Concerns Grow After Gasoline Demand Slides Most In 16 Years

Courtesy of ZeroHedge. View original post here.

Two weeks ago, we reported that when Goldman observed the latest gasoline demand data, it said that either something must be wrong with the data, or the US is in a recession: as the firm's commodity analyst Damien Courvalin put it, such a steep drop in in US gasoline demand "would require a US recession." He added that "implied demand data points to US gasoline demand in January declining 460 kb/d or 5.2% year-on-year. In the absence of a base effect, such a decline has only occurred in four periods since 1960 during which time PCE contracted."

Bloomberg's ...

more from Tyler


Standing Rock Protesters Face Mandatory Evacuation Deadline

By insidesources. Originally published at ValueWalk.

A camp that began for the water ended in flames on Wednesday afternoon as law enforcement moved to close the Dakota Access Pipeline protest camps. Prior to the mandatory evacuation deadline, protesters set fire to many of their remaining structures, arguing that this ceremonial destruction was the only way to prevent the area from being desecrated by law enforcement. A mandatory evacuation deadline had been set for 2 pm, but nearly two hours later, law enforcement remained on the perimeter, encouraging protesters to leave on their own.

The mandatory evacuation deadline was the final stage in process that had begun on Tuesday, when law enforcement set up a roadblock near the camp’s southern gate. At that time, they shut down traffic into the ca...

more from ValueWalk

Phil's Favorites

Cincarious Research's outdated note on FireEye, posted at Zero Hedge

Note: Cincarious Research contributed the article LifeLock Willing To Give FireEye $16 Per Share In Takeover Offer - Sources to Zero Hedge. It appears to be fake - or at least old - news.

Read this: Who or what is “Cincarious Research?”

Cincarious Research writes,

LifeLock is looking to revamp itself with a purchase of FireEye according to a few of our sources in the security space that are privy to the on-going conversation. We were told the company is seeking to expand offerings and the added cyber-security depth from FireEye on the government level is what LifeLock wants, badly. The deal is set for $16 per share for a total va...

more from Ilene

Kimble Charting Solutions

Gold & Silver; Knocking on breakout door again!

Courtesy of Chris Kimble.

Silver and Gold have continued to head lower since highs reached back in 2011. Is the 6-year bear market nearing an end?

Below looks at the Silver/Gold ratio over the past decade. To be long and strong Silver and Gold, the preference would be for this ratio to be heading higher.


The ratio has formed a clean falling channel (series of lower highs and lower lows) inside of (1). Three different times it knocked on the underside of falling...

more from Kimble C.S.

Market News

News You Can Use From Phil's Stock World


Financial Markets and Economy

Oil Sands Batter Major Explorers' Reserves as Rout Sinks Value (Bloomberg)

Oil-sands investments in Western Canada that gobbled tens of billions of dollars over the past decade are proving an Achilles heel for some of the world’s biggest energy producers.

A definitive breakdown of the gloomy state of Wall Street (Business Insider)

Don't be fooled by the strong rebound in Wall Street trading revenues at the end of 2016: Investment banks still had a lousy year.


more from Paul

Chart School

Market Pause

Courtesy of Declan.

Nothing really to add to yesterday. Markets took minor hits, but there was little intraday spread. The biggest spread was in the Russell 2000 which was underperforming heading into today's session. It reversed most of yesterday's gains, but it has some way to go before it begins challenging the breakout

The New Lows and Highs is in a secular bullish pattern, and it will take continued pressure in spike lows to generate a sustained sell off - none of which is happening here.


more from Chart School

Digital Currencies

It's Time To Beat Up On Credit Suisse and Their Woefully Misinformed Bitcoin Advice

Courtesy of Reggie Middleton at Zero Hedge

Credit Suisse has been posting cryptocurrency advisories over the last few weeks. They are quite one-sided, although couched in the appearance of objectivity. To explain why it's couched in the appearance of objectivity, and not actually objective, let me give you some background. 

The Obama administration enacted a law known as the Fiduciary Rule, as per Investopedia

The Department of Labor’s definition of a fiduciary demands that advisors act in the best interests of their clients, and to put their clients' interests above their own. It leaves no room for advisors to conce...

more from Bitcoin

Members' Corner

Lumber Liquidators Leukemia?

Courtesy of The Nattering Naybob

Phil – LL –   "I can see the ad campaign now: "Our lumber hardly kills you!" 

We Nattered... Today Feb 23, 2016 down -19.5% premarket from $14.21 to $11.27.   

Somebody forgot to convert feet to meters. The CDC said it made an ERROR in the Feb 10th report and had used an incorrect value to calculate ceiling height, which meant its estimates of the airborne concentration of cancer-causing formaldehyde were about three times lower than they should have been. 

Considering myeloid leukemia, some cancers and formaldehyde are linked at the hip, wonder if overexposure had anything to do with the CEO's leukemia?  

LL subsequently went to $19.67 on Sept 30th and has since cooled down to $15....

more from Our Members


Swing trading portfolio - week of February 20th, 2017

Reminder: OpTrader is available to chat with Members, comments are found below each post.


This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...

more from OpTrader

Mapping The Market

NSA May Be Withholding Intel from President Trump

By Jean Luc

These GOP guys were so worried about Hillary's email server and now we find out that we had something close to a Russian mole in the White House. In the meantime, Trump keeps on using his unsecured phone, had high level conversation in his resort in front of dinner guests! It's getting so bad that rumors are now circulating that the NSA is not sharing information with the WH:

NSA May Be Withholding Intel from President Trump


….Our spies have had enough of these shady Russian connections—and they are starting to push back….In light of this, and out of worries about the White House’s ability to keep secrets, some of our spy agencies have begun withholding intelligence fro...

more from M.T.M.


Phil's Stock World's Las Vegas Conference!

Learn option strategies and how to be the house and not the gambler. That's especially apropos since we'll be in Vegas....

Join us for the Phil's Stock World's Conference in Las Vegas!

Date:  Sunday, Feb 12, 2017 and Monday Feb 13, 2017            

Beginning Time:  9:30 to 10:00 am Sunday morning

Location: Caesars Palace in Las Vegas


Caesars has offered us rooms for $189 on Saturday night and $129 for Sunday night but rooms are limited at that price.

So, if you are planning on being in Vegas (Highly Recommended!), please sign up as soon as possible by sending...

more from Promotions


The Medicines Company: Insider Buying

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

I'm seeing huge insider buying in the biotech company The Medicines Company (MDCO). The price has already moved up around 7%, but these buys are significant, in the millions of dollars range. ~ Ilene




Insider transaction table and buying vs. selling graphic above from

Chart below from


more from Biotech

All About Trends

Mid-Day Update

Reminder: Harlan is available to chat with Members, comments are found below each post.

Click here for the full report.

To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

FeedTheBull - Top Stock market and Finance Sites

About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>

As Seen On:

About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>